Sperogenix Therapeutics is a platform company dedicated to developing and commercializing rare disease therapeutics in China with focus on mid-to-late clinical stage and commercial stage products. With prioritized therapeutic areas, such as Pulmonary Vascular Disorders, Neurological Disorders, Inherited Metabolic Diseases, and Non-oncology Hematology Disorders, Sperogenix is dedicated to establishing an innovative commercial model tailored to the China rare disease field, in order to provide affordable and reliable products and services to Chinese physicians and patients. Sperogenix was founded in 2019 and is backed by biopharma industry blue chip investors including Lilly Asia Ventures (LAV) and Morningside Venture in the A-round financing.